Cargando…
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study
BACKGROUND: Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy of platinum/gemcitabine combinations. The aim of this prospective study was to...
Autores principales: | Tibaldi, Carmelo, Camerini, Andrea, Tiseo, Marcello, Mazzoni, Francesca, Barbieri, Fausto, Vittimberga, Isabella, Brighenti, Matteo, Boni, Luca, Baldini, Editta, Gilli, Annalisa, Honeywell, Richard, Chartoire, Myriam, Peters, Godefridus J., Giovannetti, Elisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265283/ https://www.ncbi.nlm.nih.gov/pubmed/30405211 http://dx.doi.org/10.1038/s41416-018-0307-3 |
Ejemplares similares
-
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019) -
Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013) -
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017) -
Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase
por: Narvaiza, Iñigo, et al.
Publicado: (2009) -
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients
por: Serdjebi, Cindy, et al.
Publicado: (2015)